Home›Trial›NCT06104449
🔬NCT06104449Phase 1ACTIVE NOT RECRUITING

A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

Study Summary

The purpose of this study is to assess the efficacy and safety of opevesostat in the treatment of Japanese men with metastatic castration-resistant prostate cancer (mCRPC) previously treated with Next Generation Hormonal Agent (NHA) and taxane-based chemotherapy.

Conditions
Prostatic NeoplasmsMetastatic Castration-Resistant Prostate Cancer
Interventions / Drugs
OpevesostatDexamethasoneFludrocortisone acetateHydrocortisone
View on ClinicalTrials.gov ↗
Sponsor
MRK
Merck & Co
Oncology/Vaccines
F34/100
Study Details
Enrollment6 participants
Primary Completion—
Lead SponsorMerck Sharp & Dohme LLC
Data Retrieved2026-04-11 02:55:36.205158+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.